<DOC>
	<DOCNO>NCT01914666</DOCNO>
	<brief_summary>The purpose study assess long term safety duloxetine participant Chronic Low Back Pain ( CLBP ) .</brief_summary>
	<brief_title>An Open Label Extension Study Duloxetine ( LY248686 ) Participants With Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>( Consecutive Participants ) : Participants complete 15week administration phase 3 clinical study Duloxetine hydrochloride participant CLBP , study HMGY ( NCT01855919 ) Female participant childbearing potential must test negative ( ) pregnancy test ( New Participants ) : Participants CLBP present precede 6 month long Participants use nonsteroidal antiinflammatory drug CLBP le 14 day average per month past 3 month le 14 day one month prior study Participants score â‰¥4 Brief Pain Inventory ( BPI ) average pain score participation study Female participant childbearing potential must test negative ( ) pregnancy test ( Consecutive Participants ) : Participants serious unstable cardiovascular , hepatic , renal , metabolic , respiratory , hematologic illness , symptomatic peripheral vascular disease , medical condition psychiatric condition , opinion investigator , would compromise participation likely lead hospitalization course study Participants alanine aminotransferase aspartate aminotransferase high 100 International Units per Liter ( IU/L ) total bilirubin high 1.6 milligram per deciliter ( mg/dL ) Participants serum creatinine level high 2.0 mg/dL , renal transplantation receive renal dialysis Participants diagnosis seronegative spondyloarthropathy rheumatoid arthritis Participants primary painful condition due CLBP Participants uncorrected thyroid disease , uncontrolled narrowangle glaucoma , history uncontrolled seizure , uncontrolled poorly control hypertension Participants treat monoamine oxidase inhibitor ( MAOI ) within 14 day potential need use MAOI study within 5 day discontinuation study drug Participants answer `` yes '' question active suicidal ideation/intent/behaviors occur within past month ( Columbia Suicide Severity Rating Scale , Suicide Ideation section Questions 4 5 ; Suicidal Behavior section ) Pregnant participants participant breastfeed , wish pregnant clinical trial period Participants use appropriate contraceptive method want use participation study one month end administration investigational drug Participants consider inappropriate participation study medical reason judge investigator ( New Participants ) : Participants serious unstable cardiovascular , hepatic , renal , metabolic , respiratory , hematologic illness , symptomatic peripheral vascular disease , medical condition psychiatric condition , opinion investigator , would compromise participation likely lead hospitalization course study Participants alanine aminotransferase aspartate aminotransferase high 100 IU/L total bilirubin high 1.6 mg/dL Participants serum creatinine level high 2.0 mg/dL , renal transplantation receive renal dialysis Participants diagnosis seronegative spondyloarthropathy rheumatoid arthritis Participants primary painful condition due CLBP Participants history low back surgery Participants previous diagnosis psychosis , bipolar disorder , schizoaffective disorder Participants major depressive disorder determine use depression module MiniInternational Neuropsychiatric Interview Participants uncorrected thyroid disease , uncontrolled narrowangle glaucoma , history uncontrolled seizure , uncontrolled poorly control hypertension Participants treat MAOI within 14 day potential need use MAOI study within 5 day discontinuation study drug Participants answer `` yes '' question active suicidal ideation/intent/behaviors occur within past month ( Columbia Suicide Severity Rating Scale , Suicide Ideation section Questions 4 5 ; Suicidal Behavior section ) Participants know hypersensitivity multiple medication Participants nonambulatory require use crutch walker Participants history substance abuse dependence within past year , exclude nicotine caffeine Participants positive urine drug screen substance abuse Participants receive treatment within last 30 day drug receive regulatory approval indication Participants previous exposure duloxetine complete / withdrawn study investigate duloxetine Pregnant participants participant breastfeed , wish pregnant clinical trial period Participants use appropriate contraceptive method want use participation study one month end administration investigational drug Participants consider inappropriate participation study medical reason judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Chronic Low Back Pain</keyword>
	<keyword>CLBP</keyword>
</DOC>